Modeling complex decay profiles of hepatitis B virus during antiviral therapy

Hepatology

Volumn 49, Issue 1, 2009, Pages 32-38

  Dahari, Harel ^a   Shudo, Emi ^b   Ribeiro, Ruy M ^b   Perelson, Alan S ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RIBAVIRIN; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; CELL PROLIFERATION; DISEASE SIMULATION; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS B; HEPATITIS B VIRUS; KINETICS; LIVER CELL; PRIORITY JOURNAL; REBOUND; BIOLOGICAL MODEL; DRUG EFFECT; HUMAN; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; KINETICS; MODELS, BIOLOGICAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 58949084496     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22586     Document Type: Article

References (31)

1. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: Summary of a clinical research workshop. HEPATOLOGY 2007; 45:1056-1075.
2. Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini S, et al. Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed. HEPATOLOGY 2001;34:1012-1020.
3. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. HEPATOLOGY 2007;46: 254-265.
4. Wein LM, D'Amato RM, Perelson AS. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theor Biol 1998;192:81-98.
5. Callaway DS, Perelson AS. HIV-1 infection and low steady state viral loads. Bull Math Biol 2002;64:29-64.
6. Huang Y, Rosenkranz SL, Wu H. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math Biosci 2003;184:165-186.
7. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. HEPATOLOGY 2007;46:16-21.
8. Dahari H, Lo A, Ribeiro RM, Perelson AS. Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy. J Theor Biol 2007; 247:371-381.
9. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.
10. Lau GK, Tsiang M, Hou J, Yuen S, Carman WF, Zhang L, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis Binfected Chinese patients: A viral dynamics study. HEPATOLOGY 2000;32: 394-399.
11. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. HEPATOLOGY 1999;29:1863-1869.
12. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996;93:4398-4402.
13. Dahari H, Major M, Zhang X, Mihalik K, Rice CM, Perelson AS, et al. Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production. Gastroenterology 2005; 128:1056-1066.
14. Theise ND, Nimmakayalu M, Gardner R, Illei PB, Morgan G, Teperman L, et al. Liver from bone marrow in humans. HEPATOLOGY 2000;32:11-16.
15. Neumann AU. Hepatitis B viral kinetics: A dynamic puzzle still to be resolved. HEPATOLOGY 2005;42:249-254.
16. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91.
17. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-829.
18. Hezode C, Chevaliez S, Bouvier-Alias M, Roudot-Thoraval F, Brillet R, Zafrani ES, et al. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol 2007;46:791-796.
19. Colombatto P, Civitano L, Bizzarri R, Oliveri F, Choudhury S, Gieschke R, et al. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. Antivir Ther 2006;11:197-212.
20. Perelson AS. Modelling viral and immune system dynamics. Nat Rev Immunol 2002;2:28-36.
21. Zeuzem S, de Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997;27:431-436.
22. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.
23. Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. HEPATOLOGY 2003;38:4-13.
24. Summers J, Jilbert AR, Yang W, Aldrich CE, Saputelli J, Litwin S, et al. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci U S A 2003;100:11652-11659.
25. Ciupe SM, Ribeiro RM, Nelson PW, Dusheiko G, Perelson AS. The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc Natl Acad Sci U S A 2007;104:5050-5055.
26. Gowans EJ, Burrell CJ, Jilbert AR, Marmion BP. Detection of hepatitis B virus DNA sequences in infected hepatocytes by in situ cytohybridisation. J Med Virol 1981;8:67-78.
27. Govindarajan S, Conrad A, Lim B, Valinluck B, Kim AM, Schmid P. Study of preneoplastic changes of liver cells by immunohistochemical and molecular hybridization techniques. Arch Pathol Lab Med 1990;114: 1042-1045.
28. Bannasch P, Haertel T, Su Q. Significance of hepatic preneoplasia in risk identification and early detection of neoplasia. Toxicol Pathol 2003;31: 134-139.
29. Mason WS, Jilbert AR, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci U S A. 2005;102:1139-1144.
30. Heathcote E, Gane E, DeMan R, Lee S, Flisiak R, Manns MP, et al. A randomized, double-blind, comparison of TenofovirDF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103 [Abstract]. HEPATOLOGY 2007; 46(Suppl):861A.
31. Reluga TC, Dahari H, Perelson AS. Analysis of hepatitis C virus infection models with hepatocyte homeostetis. SIAM J Appl Math. In press.